Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Eli Lilly
Biotech
Kailera, Hengrui to advance oral obesity drug into 2 new trials
Kailera and its China partner Hengrui have released promising top-line results from a phase 2 trial of their oral version of obesity drug ribupatide.
Kevin Dunleavy
Feb 10, 2026 9:25am
Lilly buys Orna in $2.4B deal to enter in vivo CAR-T arena
Feb 9, 2026 8:41am
Lilly, Innovent pen $8.8B collab 'beyond traditional licensing'
Feb 9, 2026 6:45am
Lilly drops 3 clinical programs, including Prevail gene therapy
Feb 4, 2026 12:33pm
Lilly joins platform biotech's Repertoire with $1.9B deal
Jan 29, 2026 6:30am
Lilly pens $1.1B pact to work on hearing loss gene editing med
Jan 28, 2026 7:00am
